<DOC>
	<DOC>NCT01255761</DOC>
	<brief_summary>Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis</brief_summary>
	<brief_title>A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description>RA0064 is a Phase 4, multicenter, randomized, 52-week study. All eligible subjects will receive open label Cimzia 400 mg at Weeks 0, 2 and 4, followed by Cimzia 200 mg every 2 weeks at Weeks 6 to 50 for the treatment of moderate to severe rheumatoid arthritis. All subjects will be assessed using the 2 assessment tools: the subject-based Routine Assessment of Patient Index (RAPID3) and the investigator-based Clinical Disease Activity Index (CDAI)</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects 18 years of age or older Subjects with a diagnosis of Adultonset Rheumatoid Arthritis of at least 3 months as defined by the 1987 American College of Rheumatology (ACR) classification criteria Subjects with active Rheumatoid Arthritis as defined by: 4 tender joints (28 joint count) at Screening and Baseline Visits; and 4 swollen joints (28 joint count) at Screening and Baseline Visits Subjects who have had an unsatisfactory response or intolerance to at least 1 traditional Diseasemodifying Antirheumatic Drugs (DMARD) Subjects must not have a diagnosis of any other inflammatory Arthritis Subjects must not have greater than 3 Arthroplasties due to Rheumatoid Arthritis and/or Steinbrocker IV Functional Capacity Subjects must not have a secondary noninflammatory type of Arthritis that would interfere with study evaluation Subjects must not be diagnosed with Fibromyalgia with sufficient symptoms requiring treatment Subjects must not have a history of Infected Joint Prosthesis Subjects must not have discontinued biological therapy for their Rheumatoid Arthritis due to Severe Hypersensitivity Reaction or Anaphylactic Reaction Subjects must not have received more than 2 anti Tumor Necrosis Factor (TNF) agents prior to enrollment Subjects must not have received treatment with Abatacept and/or Rituximab or have received any experimental or approved B cell therapeutic agent Subjects must not have a history of chronic alcohol or drug abuse Subjects must not have known hypersensitivity to any components of the investigational medicinal product Subjects must not have a history of chronic infections, recent serious or lifethreatening infection within 6 months or any current sign or symptom that may indicate an infection Subjects must not have a history of a Blood Dyscrasias Subjects with known Tuberculosis (TB) Disease, high risk of acquiring TB or latent TB infection Subjects must not be at high risk of infection Subjects must not have a history of Lymphoproliferative Disorder including Lymphoma signs and symptoms suggestive of Lymphoproliferative Disease Subjects must not have concurrent acute or chronic Viral Hepatitis B or C Subjects must not have known Human Immunodeficiency Virus (HIV) infection Subject must not have concurrent Malignancy or history of Malignancy Subjects must not have a current or recent history of severe, progressive, and/or uncontrolled Renal, Hepatic, Hematological, Gastrointestinal, Endocrine, Pulmonary, Cardiac, Neurological or Cerebral Disease Subjects must not have Class III or IV Congestive Heart Failure Subjects must not have history of, or suspected Demyelinating Disease of the Central Nervous System Subjects must not have a history of adverse reaction to Polyethylene Glycol (PEG) Subjects must not have significant laboratory abnormalities which in the investigators judgment would make the subject unsuitable for inclusion Subjects must not have a known history or clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, Nontuberculous Mycobacteria, Blastomyces or Aspergillus Subject must not have a known history of or be currently diagnosed with Systemic Lupus Erythematosus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>CDAI</keyword>
	<keyword>RAPID3</keyword>
</DOC>